• Qlife will receive approximately SEK 2.7 million from a global pharmaceutical partner for a fully partner-funded product-readiness phase.
• Total partner funding reaches approximately SEK 4.2 million, including SEK 1.5 million for initial feasibility work completed following its September 2026 announcement.
• The program comprises 12 weeks of technical work followed by four weeks of mobilization, focusing on sample preparation and testing workflow integration.
• Successful completion and a subsequent agreement would enable a clinical development and commercialization partnership covering formal development through market clearance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qlife Holding AB published the original content used to generate this news brief via Cision (Ref. ID: 202611111130BITN____UKPR__SV_20261111-BIT-7833-0) on November 11, 2026, and is solely responsible for the information contained therein.